How good are current approaches to nonclinical evaluation of abuse and dependence?

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 588-595

  Moser, Paul ^a   Wolinsky, Toni ^a   Duxon, Mark ^a   Porsolt, Roger D ^a  

^a Porsolt and Partners Pharmacology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE; DIAZEPAM; DIPHENHYDRAMINE; DULOXETINE; ERYTHROPOIETIN; FENTANYL; FLUOXETINE; HYDROCODONE; METHYLPHENIDATE; MODAFINIL; MORPHINE; OXYCODONE; PAROXETINE; PROPOFOL; SALVINORIN A; SILDENAFIL; STEROID; VENLAFAXINE;

DRUG DEPENDENCE; DRUG LEGISLATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LIABILITY; PLACE PREFERENCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; TELEMETRY; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; SELF ADMINISTRATION; SPECIES SPECIFICITY; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TELEMETRY;

EID: 79951966422     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169979     Document Type: Review

References (53)

1. Ator NA and Griffiths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70:S55-S72. (Pubitemid 36577515)
2. Beardsley PM, Hayes BA, and Balster RL (1990) The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252: 953-959. (Pubitemid 20127396)
3. Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, and Harris LS (2004) Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol 12:163-172. (Pubitemid 38988712)
4. Bergman J and Spealman RD (1986) Some behavioral effects of histamine H1 antagonists in squirrel monkeys. J Pharmacol Exp Ther 239:104-110. (Pubitemid 16006343)
5. Black K, Shea C, Dursun S, and Kutcher S (2000) Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25:255-261. (Pubitemid 30641002)
6. Blokhina EA, Dravolina OA, Bespalov AY, Balster RL, and Zvartau EE (2004) Intravenous self-administration of abused solvents and anesthetics in mice. Eur J Pharmacol 485:211-218. (Pubitemid 38134417)
7. Bogle KE and Smith BH (2009) Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences.Curr Drug Abuse Rev 2:157-176.
8. Brady JV and Fischman MW (1985) Assessment of drugs for dependence potential and abuse liability: an Overview, in Behavioral Pharmacology: The Current Status (Seiden LS and Balster RL eds) pp 361-382, Alan R Liss, New York.
9. Chan R, Irvine R, and White J (1999) Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat. Eur J Pharmacol 368:25-33. (Pubitemid 29106411)
10. Colpaert FC (1987) Drug discrimination: methods of manipulation, measurement and analysis, in: Methods of Assessing the Reinforcing Properties of Abused Drugs (Bozarth MA ed) pp 341-372. Springer Verlag, New York.
11. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, and Kowalczyk WJ (2008) Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33:1179-1191. (Pubitemid 351367537)
12. Deroche-Gamonet V, Darnaudéry M, Bruins-Slot L, Piat F, Le Moal M, and Piazza PV (2002) Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161:387-395. (Pubitemid 34595790)
13. European Medicines Agency (2006) Guideline on the non-clinical investigation of the dependence potential of medicinal products. European Medicines Agency, London, United Kingdom.
14. Farré M and Camí J (1991) Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 86:1601-1606.
15. Gerak LR and France CP (1996) Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 276:523-531.
16. Gold LH and Balster RL (1996) Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126: 286-292. (Pubitemid 26276699)
17. Goudie AJ and Leathley MJ (1991) Evaluation of the dependence potential of the selective 5-H1A agonist ipsapirone in rats and of its effects on benzodiazepine withdrawal. Psychopharmacology (Berl) 103:529-537.
18. Grant KA and Johanson CE (1987) Diazepam self-administration and resistance to extinction. Pharmacol Biochem Behav 28:81-86. (Pubitemid 17142745)
19. Griffiths RR, Lukas SE, Bradford LD, Brady JV, and Snell JD (1981) Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology (Berl) 75: 101-109. (Pubitemid 12228813)
20. Ista E, van Dijk M, Gamel C, Tibboel D, and de HoogM(2008) Withdrawal symptoms in critically ill children after long-term administration of sedatives and/or analgesics: a first evaluation. Crit Care Med 36:2427-2432.
21. Jasinski DR (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14:53-60.
22. Jorge JC, Velázquez KT, Ramos-Ortolaza DL, Lorenzini I, Marrero J, and Maldonado-Vlaar CS (2005) A testosterone metabolite is rewarding to ovariectomized female rats. Behav Neurosci 119:1222-1226. (Pubitemid 41598735)
23. Lamprea MR, Cardenas FP, Silveira R, Morato S, and Walsh TJ (2000) Dissociation of memory and anxiety in a repeated elevated plus maze paradigm: forebrain cholinergic mechanisms. Behav Brain Res 117:97-105.
24. Lile JA, Morgan D, Birmingham AM, Wang Z, Woolverton WL, Davies HM, and Nader MA (2002) The reinforcing efficacy of the dopamine reuptake inhibitor 2β-propanoyl-3β-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther 303:640-648. (Pubitemid 35231236)
25. Lin D, Koob GF, and Markou A (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl) 145:283-294. (Pubitemid 29393478)
26. Little HJ (1991) The benzodiazepines: anxiolytic and withdrawal effects. Neuropeptides 19:11-14.
27. Maldonado R and Rodríguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326-3331. (Pubitemid 37465736)
28. McNally GP and Carrive P (2006) A telemetric examination of cardiovascular function during the development of, and recovery from, opiate dependence in rats. Physiol Behav 88:55-60. (Pubitemid 43795957)
29. Mierzejewski P, Koroś E, Goldberg SR, Kostowski W, and Stefański R (2003) Intravenous self-administration of morphine and cocaine: a comparative study. Pol J Pharmacol 55:713-726. (Pubitemid 37540870)
30. Moser P, Wolinsky T, Castagné C, and Duxon M (2010) Current approaches and issues in non-clinical evaluation of abuse and dependence. J Pharmacol Toxicol Methods doi:10.1016/j.vascn.2010.09.004.
31. Moser P (2009) Evaluation of morphine withdrawal effects using telemetry. J Pharmacol Toxicol Methods 60:224.
32. Nader MA, Grant KA, Davies HM, Mach RH, and Childers SR (1997) The reinforcing and discriminative stimulus effects of the novel cocaine analog 2β-propanoyl-3β-(4-tolyl)-tropane in rhesus monkeys. J Pharmacol Exp Ther 280:541-550. (Pubitemid 27171311)
33. NIDA Research Report (2005) Prescription drugs: abuse and addiction. NIDA publication number 05-4881, National Institute on Drug Abuse, Bethesda, MD.
34. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.
35. Parker G and Blennerhassett J (1998) Withdrawal reactions associated with venlafaxine. Aust N Z J Psychiatry 32:291-294. (Pubitemid 28211709)
36. Perahia DG, Kajdasz DK, Desaiah D, and Haddad PM (2005) Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disorders 89:207-212. (Pubitemid 41740850)
37. Pétursson H (1994) The benzodiazepine withdrawal syndrome. Addiction 89:1455-1459.
38. Roberts DC, Phelan R, Hodges LM, Hodges MM, Bennett B, Childers S, and Davies H (1999) Self-administration of cocaine analogs by rats. Psychopharmacology 144:389-397. (Pubitemid 29307264)
39. Roux S, Sablé E, and Porsolt RD (2004) Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on biological function. Curr Protoc Pharmacol 10:10.1-10.23.
40. Saban A and Flisher AJ (2010) The association between psychopathology and substance use in young people: a review of the literature. J Psychoactive Drugs 42:37-47.
41. Shoaib M, Stolerman IP, and Kumar RC (1994) Nicotine-induced place preferences following prior nicotine exposure in rats. Psychopharmacology 113:445-452. (Pubitemid 24150492)
42. Smith RF (2003) Animal models of periadolescent substance abuse. Neurotoxicol Teratol 25:291-301.
43. Thomas A, Nallur DG, Jones N, and Deslandes PN (2009) Diphenhydramine abuse and detoxification: a brief review and case report. J. Psychopharmacol 23:101-105.
44. Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613-672.
45. U.S. Food and Drug Administration (2010) Assessment of abuse potential of drugs: draft guidance. US Department of Health and Human Services. U.S. Food and Drug Administration, Rockville, MD.
46. Ward KW and Smith BR (2004a) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
47. Ward KW and Smith BR (2004b) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 32:612-619. (Pubitemid 38668153)
48. Wood RI (2004) Reinforcing aspects of androgens. Physiol Behav 83:279-289.
49. Weerts EM, Fantegrossi WE, and Goodwin AK (2007) The value of nonhuman primates in drug abuse research. Exp Clin Psychopharmacol 15:309-327. (Pubitemid 47445259)
50. West R and Gossop M (1994) Overview: a comparison of withdrawal symptoms from different drug classes. Addiction 89:1483-1489. (Pubitemid 24343909)
51. Wilson C, Canning P, and Caravati EM (2010) The abuse potential of propofol. Clin Toxicol (Phila) 48:165-170.
52. Young AM and Woods JH (1981) Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self-administration histories. J Pharmacol Exp Ther 218:720-727. (Pubitemid 11005144)
53. Zajecka J, Tracy KA, and Mitchell S (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291-297. (Pubitemid 27362484)